Drug Trial Radar · NCT07895524
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 23, 2026
Primary completion
Oct 19, 2027
Study completion Nov 28, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. Researchers are doing this trial to learn if a trial medicine called MK-8690 can treat symptoms of active RA in people who are taking MTX. The goal of this study is to learn if MK-8690 works better than placebo to improve RA symptoms.
Conditions
- Rheumatoid Arthritis
Interventions
MK-8690Combination product
Solution for SC injection
PlaceboCombination product
Solution for SC injection
Methotrexate (MTX)Drug
Background therapy - variable dose strength with route of administration per approved product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.